Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726641 | 1.00 | CDK2 (0.71) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5726781 | 1.00 | CDK2 (0.71) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5726439 | 0.84 | CDK2 (0.72) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5727149 | 0.84 | CDK2 (0.72) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5726414 | 0.84 | CDK2 (0.72) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5726044 | 0.83 | CDK2 (0.68) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5726620 | 0.83 | CDK2 (0.68) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5725824 | 0.83 | CDK2 (0.68) | CDK2CCNE1CDK5NPC1RAB9A | |
| SCHEMBL5725799 | 0.83 | CDK2 (1.00) | CDK2CCNE1CDK5ALDH1A1SMN1; SMN2 | |
| SCHEMBL5726796 | 0.83 | CDK2 (0.82) | CDK2CCNE1CDK5ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1286835-C | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2006-11-29 | — | — | CN | claimed |
| EP-1406899-B1 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2006-11-15 | — | — | EP | claimed |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | claimed |
| CN-1531535-A | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | — | 2004-09-22 | — | — | CN | claimed |
| CN-1286835-C | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2006-11-29 | — | — | CN | disclosed |
| EP-1724270-A2 | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | Pfizer Italia S.r.l. (IT) | 2006-11-22 | — | — | EP | disclosed |
| EP-1406899-B1 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2006-11-15 | — | — | EP | disclosed |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | disclosed |
| CN-1531535-A | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | — | 2004-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | CDK2, CDK1, CDKN1A | CDK2 1/4885CCNE1 6/4885CDK5 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.